COPENHAGEN – Novo Nordisk A/S (CPH:NOVO-B) ended last week with a modest gain, but the stock failed to keep pace with the broader Danish market rally, and thin trading volumes suggest investors are adopting a wait-and-see approach ahead of the company’s first-half earnings report in August.
Novo’s B shares closed Friday at DKK 326.90, down 1.5% on the day, yet still up 2.8% for the week. In contrast, the OMX Copenhagen 25 index surged 5.5% over the same period, leaving Novo trailing the benchmark by roughly 2.6 percentage points. The underperformance highlights a lack of fresh catalysts for the Danish drugmaker, which has been grappling with pricing pressures and rising competition in the GLP-1 market.
Friday’s trading volume for Novo was just 2.58 million shares, representing only 45% of the stock’s 65-day average, according to MarketWatch. For the full week, turnover totaled 19.23 million shares, down from 25.66 million the previous week. The light activity suggests that while buyers pushed the stock higher into July, the rally lacks conviction from large institutional funds.
Haemophilia Data and Earnings on the Horizon
The next major event for Novo Nordisk is the presentation of haemophilia data at the ISTH Congress in Paris, scheduled for July 11–15. The company will showcase results from the FRONTIER4 study of investigational denecimig and the explorer10 study of concizumab in pediatric patients with haemophilia A or B with inhibitors. “We have a deep responsibility to meet the real-world needs of haemophilia patients,” said Chief Scientific Officer Martin Holst Lange in a June 26 newsroom update.
Following the haemophilia data, investors will focus on the company’s first-half 2026 earnings report, set for release on August 5 at 07:30 CEST. The results will be closely watched for updates on GLP-1 profit margins and the trajectory of Wegovy sales.
GLP-1 Profit Bridge Remains Key Concern
Novo Nordisk’s core challenge remains the profitability of its GLP-1 franchise. In May, the company raised its 2026 outlook for adjusted sales and operating profit, now guiding for a decline of 4% to 12% at constant exchange rates (CER), an improvement from the previous range of 5% to 13%. For the first quarter, adjusted net sales fell 4% year-over-year to DKK 70.06 billion, while adjusted operating profit slipped 6% to DKK 32.86 billion.
Wegovy, the company’s flagship obesity drug, posted a 22% increase in first-quarter sales at CER, driven by strong uptake of the oral formulation. CEO Mike Doustdar noted in the May report that “Wegovy is driving a strong start to 2026.” However, pricing headwinds and competition from new entrants continue to weigh on margins.
The warning signs emerged in February, when Novo said adjusted sales and operating profit could drop by 5% to 13% in 2026, citing U.S. price cuts, increased competition, and expiring semaglutide patents outside the U.S. Doustdar described the pricing pressure as “unprecedented,” while CFO Karsten Munk Knudsen called the compounding market unpredictable: “Predicting if and when the tide turns is really hard,” he told Reuters.
ADR Impact and Next Trading Session
Novo Nordisk’s American Depositary Receipts (NYSE:NVO) closed at $50.43 on July 2, but did not reflect Friday’s Copenhagen decline because U.S. markets were closed on July 3 for Independence Day. On Monday, traders will watch whether the ADR slides to match the Danish move or if U.S. healthcare flows sustain its recent rebound.
With no new GLP-1 updates from the company in the final part of last week, the light trading volume suggests that large long-only funds are not yet returning ahead of the August earnings. The stock’s ability to rally on thin volume may indicate short-term momentum, but a sustained upturn will likely require positive catalysts from the upcoming haemophilia data or the H1 report.
